Belgium is home to one of the world’s strongest health clusters and has long been ranked as the best country in the EU for clinical trials. However, if Belgium is to maintain this attractive clinical trial environment – and its quality healthcare system – the country needs to improve its position regarding the reuse of health data for research. BioVox spoke with Ingrid Maes from Inovigate about an upcoming report on Belgium’s real-world data initiatives and legislation, and how the country compares with the rest of Europe.
Knowledge for Growth is Belgium’s largest life sciences conference, and with a mix of thought leaders from across the ecosystem, always has a finger on the pulse of current topics. This year, the event focused heavily on data science, with a range of keynote talks and sessions dedicated to the important topic. One of the afternoon panels in particular, Understanding Data, held a lot of insights from Liesbet Peeters (Prof. Biomedical Data Sciences at Hasselt University) and Bart Vannieuwenhuyse (Data Sciences Lead at Janssen Benelux Campus).
To meet the challenges of climate change and global food demand, more VCs are investing in AgTech companies. A lot of these companies are using genetic modification to create better plant-based alternatives for animal products. One US company, Nobell Foods, is even developing casein-producing soybean plants that can be used to make plant-based cheese that tastes and melts like the real deal.
Heusden-Zolder, Belgium, Schlieren, Zürich, Switzerland, and Luxembourg, Grand Duchy of Luxembourg, 12 October 2021 – Rejuvenate Biomed NV (‘Rejuvenate’), a biomedical company developing novel combination drugs for age-related diseases, today announces a EUR 15.7 million Series B round. The funding is being used to accelerate the clinical development of Rejuvenate’s lead candidate RJx-01 in both acute and chronic sarcopenia (disuse-induced and age-related muscle failure).
Progress in the use of patient healthcare data is going slow for most countries, but some are racing ahead and setting the bar high. In Israel, the healthcare provider Maccabi has developed a system where researchers can access decades of medical records without compromising patient privacy. This incredible trove of medical data has given rise to groundbreaking academic and industry research, improving the lives of people around the world.
A woman opens her front door and looks to the sky to judge the weather. It’s sunny and inside her contact lenses, tiny microchips switch on layers of liquid crystals to protect her eyes from the bright light. Satisfied she won’t need a raincoat, the woman steps onto the street and goes about her day. It might sound like the start of a sci-fi novel, but this is the reality of Azalea Vision’s smart tech.
In the global search for more sustainable materials, one substance has recently begun attracting a lot of attention: mycelium, the white roots of fungi. VUB researcher Elise Elsacker has been studying the unique properties of mycelium and its potential for lowering environmental impact in the building and manufacturing industries, helping us move towards a circular economy.
It has been three months since the much-discussed FDA approval of Biogen’s Aduhelm, a treatment for Alzheimer’s Disease. The drug has been celebrated by some as a breakthrough for Alzheimer’s patients, but others remain highly sceptical or even openly opposed to the FDA decision. What has caused the furor? And what will this approval mean for other biotech companies developing new drugs for neurodegenerative diseases (and for the VCs backing them)?
Belgium is home to one of the world’s strongest health clusters and has long been ranked as the best country in the EU for clinical trials. However, if Belgium is to maintain this attractive clinical trial environment – and its quality healthcare system – the country needs to improve its position regarding the reuse of health data for research. BioVox spoke with Ingrid Maes from Inovigate about an upcoming report on Belgium’s real-world data initiatives and legislation, and how the country compares with the rest of Europe.
Knowledge for Growth is Belgium’s largest life sciences conference, and with a mix of thought leaders from across the ecosystem, always has a finger on the pulse of current topics. This year, the event focused heavily on data science, with a range of keynote talks and sessions dedicated to the important topic. One of the afternoon panels in particular, Understanding Data, held a lot of insights from Liesbet Peeters (Prof. Biomedical Data Sciences at Hasselt University) and Bart Vannieuwenhuyse (Data Sciences Lead at Janssen Benelux Campus).
To meet the challenges of climate change and global food demand, more VCs are investing in AgTech companies. A lot of these companies are using genetic modification to create better plant-based alternatives for animal products. One US company, Nobell Foods, is even developing casein-producing soybean plants that can be used to make plant-based cheese that tastes and melts like the real deal.
Heusden-Zolder, Belgium, Schlieren, Zürich, Switzerland, and Luxembourg, Grand Duchy of Luxembourg, 12 October 2021 – Rejuvenate Biomed NV (‘Rejuvenate’), a biomedical company developing novel combination drugs for age-related diseases, today announces a EUR 15.7 million Series B round. The funding is being used to accelerate the clinical development of Rejuvenate’s lead candidate RJx-01 in both acute and chronic sarcopenia (disuse-induced and age-related muscle failure).
Progress in the use of patient healthcare data is going slow for most countries, but some are racing ahead and setting the bar high. In Israel, the healthcare provider Maccabi has developed a system where researchers can access decades of medical records without compromising patient privacy. This incredible trove of medical data has given rise to groundbreaking academic and industry research, improving the lives of people around the world.
A woman opens her front door and looks to the sky to judge the weather. It’s sunny and inside her contact lenses, tiny microchips switch on layers of liquid crystals to protect her eyes from the bright light. Satisfied she won’t need a raincoat, the woman steps onto the street and goes about her day. It might sound like the start of a sci-fi novel, but this is the reality of Azalea Vision’s smart tech.
In the global search for more sustainable materials, one substance has recently begun attracting a lot of attention: mycelium, the white roots of fungi. VUB researcher Elise Elsacker has been studying the unique properties of mycelium and its potential for lowering environmental impact in the building and manufacturing industries, helping us move towards a circular economy.
It has been three months since the much-discussed FDA approval of Biogen’s Aduhelm, a treatment for Alzheimer’s Disease. The drug has been celebrated by some as a breakthrough for Alzheimer’s patients, but others remain highly sceptical or even openly opposed to the FDA decision. What has caused the furor? And what will this approval mean for other biotech companies developing new drugs for neurodegenerative diseases (and for the VCs backing them)?